Trevena Announces FDA Has Set PDUFA Date of August 7, 2020 for Oliceridine
March 05, 2020 07:01 ET
|
Trevena Inc.
FDA considers NDA resubmission a complete Class 2 response Updated guidance on extended cash runway, funding operations into Q1 2021 CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena,...
Trevena Resubmits New Drug Application for Oliceridine
February 10, 2020 07:01 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of Results from Special Population Studies for Oliceridine
November 20, 2019 07:00 ET
|
Trevena Inc.
No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:...
Trevena Announces Publication of Results from Phase 3 “Real World” Safety Study for Oliceridine in The Journal of Pain Research
November 20, 2019 07:00 ET
|
Trevena Inc.
Safety and tolerability demonstrated in diverse patient populations and surgeries CHESTERBROOK, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company...
Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study
November 04, 2019 07:00 ET
|
Trevena Inc.
Company expects to resubmit NDA for oliceridine in Q1 2020 Acute migraine proof-of-concept study for TRV250 initiated Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04,...
Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting
October 21, 2019 10:30 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Advances NDA Resubmission Activities for Oliceridine
August 28, 2019 16:01 ET
|
Trevena Inc.
— Completed enrollment in healthy volunteer QT study, topline data expected in Q4 2019 — — Completed characterization of inactive metabolite — — Remains on track to resubmit NDA in Q1 2020 — ...
Trevena Reports Second Quarter 2019 Results
August 07, 2019 07:00 ET
|
Trevena Inc.
— Enrollment for healthy volunteer QT study ongoing, topline data on schedule for Q4 2019 readout — — Company remains on track to resubmit NDA for oliceridine in Q1 2020 — — Cash runway as...
Trevena Announces Publication of APOLLO-2 Results in Pain Practice
June 24, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Initiation of Healthy Volunteer Study for Oliceridine
June 20, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel...